1. Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations.
- Author
-
Kanbe, Mio, Sunaga, Noriaki, Hara, Kenichiro, Sawada, Hiiru, Wakamatsu, Ikuo, Hara, Kentaro, Muto, Sohei, Sawada, Yuri, Masubuchi, Hiroaki, Sato, Mari, Miura, Yosuke, Tsurumaki, Hiroaki, Yatomi, Masakiyo, Sakurai, Reiko, Koga, Yasuhiko, Ohtaki, Yoichi, Nagashima, Toshiteru, Okano, Naoko, Kubo, Nobuteru, and Maeno, Toshitaka
- Subjects
- *
LUNG cancer , *GENETIC mutation , *EPIDERMAL growth factor receptors , *CANCER chemotherapy , *AFATINIB , *CANCER patients , *GEFITINIB , *TREATMENT effectiveness , *PROGRESSION-free survival - Abstract
Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors are standard therapeutic agents for non‐small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations remain to be fully established. Here, we report a long‐term (≥20 years from initial diagnosis) NSCLC survivor carrying EGFR L858R and L747V mutations. The patient received gefitinib monotherapy, systemic chemotherapy/chemoimmunotherapy, and local consolidative therapies for oligometastatic lesions, and responded to afatinib rechallenge with a progression‐free survival of 12 months. The current case suggests that afatinib is effective in NSCLC patients with EGFR L858R and L747V mutations and that a therapeutic approach combining appropriately timed systemic therapies with local consolidative therapies for oligometastatic lesions improves long‐term survival. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF